All posts tagged Mustafa Nevzat

The screaming need for drug companies to plug holes in left in their product pipelines–caused by patent expiries for top-selling medicines and lacklustre innovation records–are combining with strategic thinking to trigger M&A deals.

The pattern was underscored again Wednesday by U.S.-based biotech Amgen, which said it’s buying Turkey’s Mustafa Nevzat Pharmaceuticals, a maker of injectable generic drugs, in a move to expand Amgen’s presence in Turkey and the surrounding region and highlighting Western drugmakers’ desire to drive further into emerging markets.

Watson Pharmaceuticals will today formally announce that it is buying Swiss rival Actavis in a €4.5 billion ($5.92 billion) deal that will give the U.S.-based group a boost in the global rankings of generic drug makers, several people familiar with the matter said Tuesday.